v3.26.1
Consolidated Statements of Loss and Comprehensive Loss
$ in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2025
USD ($)
$ / shares
shares
Dec. 31, 2024
USD ($)
$ / shares
shares
Dec. 31, 2024
CAD ($)
shares
Consolidated Statements of Loss and Comprehensive Loss      
Research and development ("R&D") $ 18,426 $ 14,359 $ 19,603
General and administrative ("G&A") 8,033 6,039 8,205
TOTAL OPERATING EXPENSES: (26,459) (20,398) (27,808)
OTHER INCOME AND EXPENSES      
Finance income 1,360 1,003 1,371
Impairment of intangible asset   (2,905) (3,961)
Loss on derivative financial instruments   (3) (2)
Foreign exchange gain 398 1,669 2,301
NET LOSS BEFORE INCOME TAXES | $ (24,701) (20,634)  
Income tax expense | $ (172)    
NET LOSS FOR THE YEAR (24,873) (20,634) (28,099)
Item that may be reclassified to net loss      
Foreign currency translation adjustment 17 (2,099) (202)
TOTAL COMPREHENSIVE LOSS $ (24,856) $ (22,733) $ (28,301)
Basic loss per Common Share (in dollars per share) $ (1.7) $ (2.16)  
Diluted loss per Common Share (in dollars per share) (1.7) (2.16)  
Basic loss per Pre-Funded Warrant (in dollars per share) 0 0  
Diluted loss per Pre-Funded Warrant (in dollars per share) $ 0 $ 0  
Weighted average number of Common Shares, basic (in shares) | shares 14,595,771 9,564,862 9,564,862
Weighted average number of Common Shares, diluted (in shares) | shares 14,595,771 9,564,862 9,564,862